Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The standard dose influenza vaccine is an inactivated or recombinant protein-based vaccine designed to provide active immunization against infection by seasonal influenza A and B viruses. It contains hemagglutinin antigens from the strains predicted to circulate during the upcoming flu season. Standard dose refers to formulations containing 15 micrograms of hemagglutinin per virus strain per 0.5 mL dose for adults and older children. These vaccines work by stimulating the immune system to produce antibodies against the included viral antigens without causing disease. Most standard-dose vaccines are administered intramuscularly and are available as trivalent (three strains) or quadrivalent (four strains) formulations. They do not contain adjuvants (with exceptions like Fluad), and are distinct from high-dose or adjuvanted versions recommended for older adults. Mechanism of action: Induces humoral immune response by presenting inactivated viral antigens (primarily hemagglutinin) to elicit production of neutralizing antibodies that prevent infection with circulating influenza viruses[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standard dose influenza vaccine.